Previous 10 | Next 10 |
Vaxart (NASDAQ: VXRT) was a micro-cap stock at the beginning of 2020. Because of the coronavirus pandemic and market optimism about Vaxart's oral vaccine platform, the stock took off last year, running up 15 times in value. Is it still a buy, or are there warning signs? In a M...
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vaxart, Inc. (NASDAQ: VXRT) concerning the Company and its directors’ and officers’ possible violations of state laws. If you purchased Vaxart stock, would like to learn more about the...
A computational simulation model showed that a norovirus vaccine costing as much as $1,300 can still be cost saving in children under 5 The model also showed a norovirus vaccine costing $100 can be cost saving in older adults SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (G...
Investors seem to apparently reacting to not no overwhelming data from preclinical study evaluating Vaxart ([[VXRT]] -8.9%) oral vaccine candidate showing the candidate protected against lung inflammation in SARS-CoV-2 hamster models.New data showed that hamsters that received two doses of th...
New pre-clinical histology data show that Vaxart’s oral vaccine protected against lung inflammation in hamster models An article published in Nature Medicine reports data from a collaboration with Stanford University researchers on in vitro activity of Vaxart’s COV...
MRK was developing two candidates in this category - with Themis they were working on a measles-based one, and the IAVI a VSV-based one. But the company announced today that they're dropping both of them after looking at the first human Phase I data. Adverse effects in the US, Israel,...
COVID-19 shocked the stock market in 2020, causing massive disruptions in the world economy and killing a lot of innocent people. While major healthcare companies responded to this threat, the stocks that soared were tiny biotech companies, names like Novavax (NASDAQ: NVAX) , Vaxa...
In-vitro diagnostics company, Accelerate Diagnostics ([[AXDX]] +33.9%), and COVID-19 vaccine developer, Vaxart ([[VXRT]] +23.9%) operate in two entirely different industries in the healthcare sector.Given today’s steep climb in their stock prices, the two small-cap stocks share two imp...
This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors that piqued investor interest in 2020. These companies on average are unprofitable and tra...
Vaxart (VXRT) may have seen over a thirteen-fold rise in share price over the past 12-month period thanks to its COVID-19 vaccine development. That meteoric rise has not discouraged the analysts to issue bullish views on the stock despite two COVID-19 vaccine candidates receiving conditional ...
News, Short Squeeze, Breakout and More Instantly...
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2024 after the market close on Thursd...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...